GSK3915393 + nintedanib

GSK3915393 + nintedanib is an investigational combination drug intended for the treatment of idiopathic pulmonary fibrosis (IPF). **GSK3915393** is a novel, selective small molecule inhibitor of transglutaminase 2 (TG2) developed by GSK, designed to block fibrotic processes via inhibition of ECM cross-linking and myofibroblast activation[2][5]. **Nintedanib** is an approved small molecule kinase inhibitor developed by Boehringer Ingelheim that targets multiple receptor tyrosine kinases, including VEGFR, FGFR, and PDGFR, and acts as an antifibrotic by slowing pulmonary function decline[3]. Research is ongoing to establish the safety, efficacy, and pharmacokinetic properties of the combination, as GSK3915393 is being studied both as monotherapy and as an add-on to standard-of-care agents such as nintedanib for IPF. The combination may offer complementary or synergistic antifibrotic effects by targeting distinct pathways involved in the progression of pulmonary fibrosis[2].

Brand names

Vargatef

Other names

GSK3915393GSK-3915393GSK 3915393nintedanib